The generic name for Vyvanse is lisdexamfetamine dimesylate [1]. Lisdexamfetamine dimesylate is a prodrug that is converted in the body to dextroamphetamine, which is a central nervous system stimulant [1].
What is Lisdexamfetamine Dimesylate Used For?
Lisdexamfetamine dimesylate is prescribed to treat attention-deficit/hyperactivity disorder (ADHD) in children and adults [1]. It is also used to treat moderate to severe binge-eating disorder in adults [1].
How Does Lisdexamfetamine Dimesylate Work?
Lisdexamfetamine dimesylate's mechanism of action is not fully understood, but it is thought to involve modulating the activity of neurotransmitters like dopamine and norepinephrine in the brain [1]. As a prodrug, it requires metabolic conversion to become active, which may contribute to its smoother pharmacokinetic profile compared to other amphetamines [2].
When Did Lisdexamfetamine Dimesylate Patents Expire?
The patent landscape for lisdexamfetamine dimesylate is complex, involving multiple patents covering the drug substance, manufacturing processes, and formulations [3]. Information regarding the expiration of key patents can be found on specialized patent tracking websites like DrugPatentWatch.com [3]. As of early 2024, significant patent challenges and litigation have occurred surrounding the drug [4].
Are There Generic Versions of Lisdexamfetamine Dimesylate Available?
Generic versions of lisdexamfetamine dimesylate have faced legal and regulatory hurdles. While generic manufacturers have sought to market their versions, patent litigation and exclusivity periods have influenced their market entry [4].
What Are the Potential Side Effects of Lisdexamfetamine Dimesylate?
Common side effects of lisdexamfetamine dimesylate can include decreased appetite, dry mouth, insomnia, weight loss, anxiety, and irritability [1]. More serious side effects can include cardiovascular problems, psychiatric symptoms, and potential for abuse or dependence [1].
How Does Lisdexamfetamine Dimesylate Compare to Other ADHD Medications?
Lisdexamfetamine dimesylate is a stimulant medication. Other ADHD treatments include non-stimulant medications and behavioral therapies. Stimulants like lisdexamfetamine dimesylate are often considered first-line treatments due to their efficacy in managing core ADHD symptoms [5]. The choice of medication depends on individual patient factors, including response, tolerability, and presence of co-occurring conditions [5].
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022278s037,209214s007,209215s007lbl.pdf
2. https://pubmed.ncbi.nlm.nih.gov/21764005/
3. https://drugpatentwatch.com/
4. https://www.reuters.com/legal/litigation/fda-approves-first-generic-version-vyvanse-drug-maker-activis-says-2023-08-24/
5. https://www.cdc.gov/ncbddd/adhd/treatment.html